China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Artificial-intelligence-powered drug developer Insilico Medicine is set for a $10 million upfront payment from a fresh-faced ...

The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

So far this month, investors have poured $2.6 billion into follow-on rounds for public biotechs — the most ever for the ...

From cutting-edge solutions for stem cell research to 3D multi-omics for rapid identification of drug targets, this edition ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, ...

At some point in your research career, you may find yourself transitioning from academia to industry or vice versa. To best ...

Genentech, a biotechnology company that pledged last year to build a manufacturing facility in southern Wake County, said it ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...